Randomized controlled non-inferiority trial comparing therapist-guided Internet-based Cognitive behavioral therapy (ICBT), self-guided ICBT, and individual face-to-face (f2f) CBT for Obsessive-Compulsive Disorder (OCD) in adults. The primary objective is to evaluate whether ICBT is a non-inferior treatment option compared to the best possible available treatment for OCD, individual face to face (f2f) CBT. A second objective is to compare the efficacy of self-guided vs. therapist-guided ICBT. As this question has cost implications for the health system, a third objective is to carry out a health economic evaluation of both forms of ICBT, in relation to the gold standard f2f CBT. A fourth objective is to explore whether ICBT is equally suited for clinic-referred cases compared to self-referred patients. Finally, a fifth objective is to investigate whether genetic markers, in combination with clinical variables, can be employed to predict treatment outcomes with CBT in general. Research Questions: Q1: Is therapist-guided internet-based CBT (ICBT) for OCD non-inferior to face-to-face (f2f) CBT with regard to OCD symptoms, function and quality of life? Q2: Is entirely self-guided ICBT non-inferior to f2f CBT with regard to OCD symptoms, function and quality of life? Q3: Is ICBT a cost-effective treatment, compared to f2f CBT? Q4: Is there a difference in treatment outcome between self-referred and clinical referred patients? Q5: Can clinical variables and genetic markers be useful to predict which patients will benefit from CBT?
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
120
With therapist support
Mottagningen för Tvångssyndrom
Huddinge, Sweden
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Time frame: Change from baseline to treatmentweek 2, 4, 6, 8, 10 , 12, 15 and 3- and 12-month follow-up.
Clinical Global Impression - Severity (CGI-S)
Time frame: Change from baseline to treatmentweek 15, 3- and 12-month follow-up.
Global Assessment of Functioning (GAF)
Time frame: Change from baseline to treatmentweek 15, 3- and 12-month follow-up.
Structured Clinical Interview for DSM-5 (SCID-5) obsessive-compulsive and related disorders Structured Clinical Interview for DSM-5 (SCID-5) obsessive-compulsive and related disorders
Diagnostic status
Time frame: Change from baseline to treatmentweek 15, 3- and 12-month follow-up.
Yale-Brown Obsessive-Compulsive Scale - self-rated (Y-BOCS)
Time frame: Change from baseline to treatmentweek 15, 3- and 12-month follow-up.
Obsessive-Compulsive Inventory - Revised (OCI-R)
Time frame: Change from baseline to treatmentweek 15, 3- and 12-month follow-up.
Sheehan Disability Scale (SDS)
Time frame: Change from baseline to treatmentweek 15, 3- and 12-month follow-up.
Montgomery-Åsberg Depression Rating Scale - self-rated (MADRS-S)
Time frame: Change from baseline to treatmentweek 15, 3- and 12-month follow-up.
Euroqol (EQ-5D)
Time frame: Change from baseline to treatmentweek 15, 3- and 12-month follow-up.
Clinical Global Impression - Improvement (CGI-I)
Time frame: Treatmentweek 15, 3- and 12-month follow-up.
Insomnia Severity Index (ISI)
Time frame: Treatmentweek 15, 3- and 12-month follow-up.
Treatment credibility scale
Time frame: Change from baseline to treatmentweek 2.
Satisfaction with treatment scale
Time frame: Treatmentweek 15
TiC-P
Self-rated questionnaire on healthcare utilization and productivity losses in patients with a psychiatric disorder
Time frame: Treatmentweek 0, 15, 3- and 12-month follow-up.
Safety Monitoring Uniform Report Form (SMURF)
Time frame: Treatmentweek 2, 4, 6, 8, 10 , 12, 15 and 3- and 12-month follow-up.
Patient EX/RP Adherence Scale (PEAS)
Time frame: Treatmentweek 6 and 15
Working Alliance Inventory - short revised
Time frame: Change from baseline to treatment week 6 and 15
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.